Pyridopyrimidine compounds and their applications as KRAS inhibitors and in antitumor therapy
By designing and synthesizing pyridopyrimidine compounds, the challenge of targeting KRAS G12C-mutant tumors in existing technologies has been solved, achieving effective inhibition of KRAS kinase and cancer treatment effects.
Patent Information
- Application Number
- CN202611358182.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-03
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are difficult to effectively target and treat tumors associated with KRAS G12C mutations. In particular, the development of small molecule inhibitors is difficult due to the high affinity of RAS family small GTPases for guanine nucleotides and the smooth surface structure of KRAS protein molecules. Existing drugs are also difficult to cover tumors driven by mutations in other RAS subtypes such as KRAS and NRAS.
This invention provides a pyridopyrimidine compound that, through specific structural design and synthetic route, produces a compound with strong KRAS kinase inhibition ability, which can be used to prepare KRAS-targeted inhibitors and cancer treatment drugs.
It achieved effective inhibition of KRAS kinase, showing good safety and in vivo bioactivity, and has potential application value in the treatment and prevention of proliferative diseases and cancer.
Smart Images

Figure CN123106669A_ABST
Abstract
Description
Technical Field
[0001] This application belongs to the field of biomedical technology, specifically relating to a pyridopyrimidine compound and its application in KRAS inhibitors and antitumor therapy. Background Technology
[0002] Malignant tumors, as a major disease posing a serious threat to human life and health, are closely related to more than a hundred pathophysiological processes in the body. When abnormal gene mutations occur in body cells, uncontrolled and continuous division and proliferation occur. The body's own immune surveillance and growth regulation mechanisms are unable to curb this abnormal proliferation, ultimately leading to the transformation of benign lesions into malignant tumors. Globally, lung cancer has long been the leading cause of death among all types of malignant tumors, becoming the number one malignant tumor endangering human health. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is the core target of clinical diagnosis and treatment of lung cancer. Traditional clinical interventions for non-small cell lung cancer (NSCLC) primarily involve surgical resection, radiotherapy, and chemotherapy. However, these approaches have significant limitations: surgery often fails to completely eliminate microscopic lesions, resulting in a persistently high risk of postoperative tumor recurrence; radiotherapy and chemotherapy are non-specific killing agents, causing irreversible damage to normal tissues and cells while eliminating tumor cells, leading to severe toxic side effects such as bone marrow suppression, gastrointestinal reactions, and organ dysfunction, significantly reducing patient quality of life and treatment adherence. In recent years, breakthroughs have been achieved in the research and clinical application of small molecule targeted inhibitors. With their advantages of precise targeting, high efficacy, and low toxicity, they have opened up new pathways for personalized treatment of NSCLC. Previously, clinical treatment for malignant tumors primarily relied on radiotherapy and chemotherapy. Compared to the traditional radiotherapy and chemotherapy regimen for stage I and II non-small cell lung cancer, small molecule targeted drugs have rapidly become a research hotspot in the field of targeted cancer therapy due to their core advantages such as clear targets, well-defined mechanisms of action, mild toxicity and side effects, and outstanding clinical efficacy. Various small molecule compounds targeting these targets have also entered the research and development and clinical exploration stages. As early as the end of the last century, research showed that RAS family gene mutations, typically represented by KRAS G12C, are the most common oncogenic driving events in human malignant tumors. These mutations are highly prevalent in solid tumors such as lung cancer, pancreatic cancer, and colorectal cancer, and the mutation status is closely related to patient disease progression and prognosis.
[0003] At the molecular level, the KRAS G12C mutation refers to a specific mutant formed by the mutation of the 12th amino acid residue of the KRAS gene to cysteine. This mutation accounts for approximately 13% of lung adenocarcinomas, 3% of colorectal cancers, 2% of uterine cancers, and 1% of mesotheliomas. Furthermore, low-frequency KRAS gene mutations can also be detected in various malignant tumors such as pancreatic cancer, cervical cancer, bladder cancer, and gastric cancer. Despite the high clinical research value of the KRAS G12C target, targeted therapy against this signaling pathway still faces numerous technical challenges. The reasons for this are twofold. Firstly, RAS family small GTPases have extremely high affinity for guanine nucleotides, making it extremely difficult to screen and develop highly selective and active small molecule inhibitors. Secondly, the KRAS protein molecule has a relatively smooth surface structure, lacking hydrophobic cavities for stable binding of small molecule drugs, except for the GTP-binding region, which greatly increases the difficulty of drug target screening and molecular design. Constrained by these two factors, the development of KRAS-targeting inhibitors has long been slow, with very few related research results, further highlighting the urgency and significant clinical importance of developing KRAS G12C-targeted drugs. Currently, while some progress has been made in the development of covalent inhibitors targeting KRAS G12C, these drugs are only effective against the single KRAS G12C mutation subtype, making it difficult to cover tumors driven by mutations in other RAS subtypes such as KRAS and NRAS. Meanwhile, the clinical efficacy and safety of other inhibitors targeting upstream regulators and downstream effector nodes of the RAS signaling pathway have not been fully validated, failing to achieve effective control of KRAS G12C mutation-related tumors. Therefore, the development of small molecule drugs targeting KRAS G12C remains a significant challenge. In-depth basic research and drug development in this field are of crucial theoretical and clinical value for overcoming the bottlenecks in targeted therapy for malignant tumors and improving patient prognosis. Summary of the Invention
[0004] The purpose of this application is to address the shortcomings of the prior art. Based on this, the first aspect of this application provides a pyridopyrimidine compound with the structure shown in Formula I, Formula II or Formula III: Formula I; Formula II; Formula III; Where R is selected from , , , , , , , , and One of them.
[0005] In some preferred embodiments, the structural formulas of the above-mentioned pyridopyrimidine compounds are any one of formulas F1-F20: .
[0006] Their Chinese names are as follows: 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, cyclopropyl(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl) methyl ketone, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazine (-1-yl)butane-1-one, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)pentane-1-one, (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(p-tolyl) methyl ketone, (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)piperazin-1-one, (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)piperazin-1-one, (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-one) Azin-1-yl)(phenyl) ketone, (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentan-1-one, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridine) [4,3-d]pyrimidin-4-yl)piperazin-1-yl)hexane-1-one, (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridine[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenylprop-2-en-1-one, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridine[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridine[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, (E)-1-(4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, (E)-1-(4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one, (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenyl-2-propen-1-one, 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)hexane-1-one, ( 4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(p-tolyl) methyl ketone, 1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, (E)- ...)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one, (E)-1-(4-(2-(benzo[d][1,3]dioxolane-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin-5-yl)methoxy)-7-(pyrimidin ]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one, 1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentanone, ( ... Cyclo-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(cyclopropyl) methyl ketone, (E)-1-(4-(2-(benzyl(E)-1-(4-(2-(benzo[d][1,3]dioxolanecyclo-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenyl-2-propen-1-one,
[0007] More preferably, the above-mentioned pyridopyrimidine compounds have the structural formulas shown in Formula F1 or Formula F7; they have better KRAS inhibition effects.
[0008] The second aspect of this application provides a method for preparing the above-mentioned pyridopyrimidine compounds, including synthetic route one, synthetic route two, or synthetic route three, wherein synthetic route one is as follows: ; The second synthetic route is as follows: ; The third synthetic route is as follows: .
[0009] Taking compound F1 as an example, its preparation method includes the following steps: Under an inert gas atmosphere, 2,4,7-trichloro-8-fluoropyridino[4,3-d]pyrimidine, as the starting material, undergoes a nucleophilic substitution reaction with 1-tert-butyloxycarbonylpiperazine, followed by a nucleophilic substitution reaction with 1-methyl-4-piperidinemethanol under basic conditions. This is then followed by a cross-coupling reaction with 4-morpholinophenylboronic acid to obtain an aryl-modified Boc-protected intermediate. The tert-butyloxycarbonyl protecting group is removed from this intermediate under acidic conditions to obtain a piperazine-terminated intermediate. Under an inert gas atmosphere, this intermediate undergoes an acylation reaction with acryloyl chloride to give the compound shown in F1. The inert gas mentioned above can be nitrogen.
[0010] A third aspect of this application provides a pharmaceutical composition comprising the aforementioned pyridopyrimidine compounds or pharmaceutically acceptable salts thereof. The pharmaceutical composition of this application can also be used in combination with other active ingredients, provided they do not produce other adverse effects, such as allergic reactions. Furthermore, the aforementioned pharmaceutical composition includes a pharmaceutically acceptable carrier or excipient. The aforementioned pharmaceutically acceptable excipient refers to any diluent, adjuvant, and / or carrier that can be used in the pharmaceutical field. Carriers used in the pharmaceutical compositions of this application are common types available in the pharmaceutical field, including: binders, lubricants, disintegrants, solubilizers, diluents, stabilizers, suspending agents, flavoring agents, preservatives, solvents, and matrices, etc. The dosage forms of the aforementioned pharmaceutical compositions are injections, tablets, capsules, aerosols, suppositories, films, pellets, topical liniments, or ointments. Pharmaceutical formulations can be administered orally or by non-gastrointestinal routes (e.g., intravenously, subcutaneously, intraperitoneally, or topically). If certain drugs are unstable under gastric conditions, they can be formulated into enteric-coated tablets.
[0011] The clinical dosage of the pyridopyrimidine compounds or their pharmaceutically acceptable salts, or the pharmaceutical compositions described above, for use in patients can be appropriately adjusted based on: the therapeutic efficacy and bioavailability of the active ingredients in vivo, their metabolic and excretion rates, and the patient's age, sex, and stage of disease. However, the daily dose for adults should generally be 10 mg to 500 mg, preferably 50 mg to 300 mg. These preparations can be administered at regular intervals, preferably one to six times, as directed by a physician or pharmacist.
[0012] The fourth aspect of this application provides the use of the above-described pyridopyrimidine compounds or pharmaceutically acceptable salts thereof, or the above-described pharmaceutical compositions, in the preparation of KRAS-targeting inhibitors.
[0013] The fifth aspect of this application provides the use of the aforementioned pyridopyrimidine compounds or pharmaceutically acceptable salts thereof, or the aforementioned pharmaceutical compositions, in the preparation of medicaments for treating and / or preventing cancer. The cancers mentioned above are breast cancer, lung cancer, melanoma, pancreatic cancer, or prostate cancer.
[0014] The sixth aspect of this application provides the use of the above-mentioned pyridopyrimidine compounds or pharmaceutically acceptable salts thereof, or the above-mentioned pharmaceutical compositions, in the preparation of medicaments for the treatment and / or prevention of proliferative diseases. The proliferative diseases include colorectal cancer, pancreatic ductal adenocarcinoma, etc.
[0015] The beneficial effects of this application are as follows: The pyridopyrimidine compounds provided in this application have a strong ability to inhibit KRAS kinase, and have good safety evaluation and good in vivo biological activity. Therefore, they can be used as active ingredients to prepare therapeutic drugs for diseases caused by abnormal activation of KRAS kinase, and also show potential application value in the preparation of drugs for the treatment and / or prevention of proliferative diseases and cancer. Attached Figure Description
[0016] Figure 1 The figure shown is a graph of the hemolytic safety evaluation results of compound F1; Figure 2 The figure shown is a graph of the results of the in vivo toxicity test of each group on KM mice; Figure 3 The image shows the HE staining results of various organs and tissues in each group of KM mice to assess the biotoxicity of the treatment. Figure 4 The figure shown is a graph illustrating the time-dependent effect of compound F1 on H358 cells. Figure 5 The figure shown is a graph of the wound healing results of each group acting on H358 cells; Figure 6 The figure shown is a cloning experiment result diagram of each group acting on H358 cells; Figure 7 The figure shown is a graph of the AO staining test results of each group acting on H358 cells; Figure 8 The image shows the results of JC-1 staining experiments on H358 cells in each group; Figure 9 The image shows the results of ROS staining experiments on H358 cells in each group. Detailed Implementation
[0017] The following will provide a clear and complete description of the concept and technical effects of this application in conjunction with the embodiments and accompanying drawings, so as to fully understand the purpose, solution and effects of this application. It should be noted that, unless otherwise specified, the embodiments and features in the embodiments of this application can be combined with each other. The proton NMR spectra of the compounds in the embodiments of this application were determined using a Bruker ARX-400; all reagents used were analytical grade or chemically pure.
[0018] The structural formulas of compounds F1-F20 mentioned below are shown below: .
[0019] The preparation methods of compounds F1-F20 mentioned below include synthetic route one, synthetic route two, or synthetic route three; wherein, synthetic route one is as follows: ; Synthetic route two is as follows: ; Synthesis route three is: .
[0020] Example 1 A pyridopyrimidine compound, the structure of which is shown in F1, is named 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one.
[0021] Its preparation method includes the following process: (1) Preparation of tert-butyl 4-(2,7-dichloro-8-fluoropyridin[4,3-d]pyrimidin-4-yl)piperazine-1-carboxylic acid ester: 1 g of 2,4,7-trichloro-8-fluoropyridin[4,3-d]pyrimidinium (1, representing structural formula 1 in the following formula, the same below) was slowly added dropwise to a tetrahydrofuran solution containing 0.47 g of 1-tert-butyloxycarbonylpiperazine using a constant pressure titration funnel. The mixture was stirred for 2.5 h under ice bath conditions. After the reaction was completed, ethyl acetate with a volume approximately four times that of the reaction solution was added to dilute the system. The mixture was then extracted twice with sodium bicarbonate aqueous solution, and the organic phases were combined. The organic phase was then washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the target product.
[0022] (2) Add 1 g of 2,0.75 g of 1-methyl-4-piperidinemethanol to the reaction flask, use dichloromethane as solvent, add 2 d of triethylamine, heat to 30 °C, and after the reaction is complete, concentrate the reaction solution under reduced pressure to obtain a yellowish-brown oily product. To further optimize the post-processing, redissolve the above oily substance with a small amount of ethanol, and then add a large amount of ice water to crystallize.
[0023] (3) Anhydrous DMF was used as the reaction solvent. 1 g of 3, 0.95 g of 4-morpholinophenylboronic acid, 0.58 g of potassium phosphate, and 0.12 g of tetrakis(triphenylphosphine)palladium were added as catalysts. The reaction flask was sealed and the air was replaced with nitrogen three times to ensure that the reaction system was in an oxygen-free environment. The temperature was raised to 100 °C. After the reaction was completed, 5 times the volume of ethyl acetate was added to the reaction mixture for dilution. The mixture was then extracted with water three times to remove DMF from the system. The system was then filtered with diatomaceous earth to remove the tetrakis(triphenylphosphine)palladium catalyst. The solvent was removed by vacuum concentration. The mixture was then separated by silica gel column chromatography.
[0024] (4) Prepare a solvent with an equivalent ratio of dichloromethane to trifluoroacetic acid of about 10:3. After dissolving 4, stir at room temperature for 0.5 h. After the reaction is complete, add sodium bicarbonate aqueous solution dropwise to the mixture. A large amount of solid product will precipitate in the system. After separation by vacuum filtration, the target compound is obtained.
[0025] (5) Dissolve 0.65 mL of acyl chloride and triethylamine in dichloromethane, and add it dropwise to a dichloromethane solution containing 1 g of 5 under ice bath conditions. Stir at room temperature. After the reaction is complete, concentrate the reaction solution under vacuum, add an appropriate amount of methanol solution to just dissolve the product, and then add a large amount of ice water. A large amount of solid can be observed to precipitate. Filter the solution, and the solid on the filter cake is the final product.
[0026] The characterization results of compound F1 are as follows: 1H NMR(400 MHz, Chloroform-d)δ9.04(s, 1H), 8.12(d, J=8.5 Hz, 2H), 7.04(d, J=8.5 Hz, 2H), 6.62(s, 1H),6.41(d, J=16.2 Hz,1H),5.82(d, J=10.7 Hz, 1H), 4.34(s, 3H), 3.97(d, J=48.1 Hz, 12H), 3.32(s, 4H), 3.04(s, 2H), 2.82(s, 2H), 2.31(s, 2H), 2.13–1.90(m, 6H), 1.27(s, 6H).
[0027] Example 2 A pyridopyrimidine compound, the structure of which is shown in F2, is named cyclopropyl(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl) methyl ketone.
[0028] Its preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of cyclopropylformyl chloride.
[0029] The characterization results of compound F2 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),8.00–7.74 (m, 2H), 7.36–7.19 (m, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.87–3.38 (m,12H), 3.17–3.00 (m, 1H), 2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J= 12.4, 8.2, 6.1 Hz, 2H), 2.37–1.50 (m, 13H), 0.93–0.73 (m, 4H).
[0030] Example 3 A pyridopyrimidine compound, the structure of which is shown in F3, is named (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)butane-1-one.
[0031] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of n-butyryl chloride.
[0032] The characterization results of compound F3 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.95–7.70 (m, 2H), 7.50–7.17 (m, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.81–3.33 (m,12H), 3.15–2.96 0.97 (t, J =7.8 Hz, 3H).
[0033] Example 4 A pyridopyrimidine compound, the structure of which is shown in F4, is named 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)pentan-1-one.
[0034] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar equivalent of pentanoyl chloride.
[0035] The characterization results of compound F4 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.70 (ddd, J= 6.7, 5.7, 3.8 Hz, 4H), 3.63–3.48 (m, 9H), 3.10–3.02 (m, 1H), 2.86 (ddd, J =12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.35 (t, J =8.2 Hz, 2H), 2.25 (s, 2H), 2.21–2.11 (m, 1H), 2.07 (dtd, J = 12.1, 6.0, 3.5Hz, 2H), 1.81–1.64 (m, 7H), 1.64–1.54 (m, 2H), 1.38 (h, J = 7.2 Hz, 2H), 0.92(t, J = 7.4 Hz, 3H).
[0036] Example 5 A pyridopyrimidine compound, the structure of which is shown in F5, is named (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(p-tolyl) methyl ketone.
[0037] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of p-methylbenzoyl chloride.
[0038] The characterization results of compound F5 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.49–7.43 (m, 2H), 7.34–7.28 (m, 2H), 7.16–7.10 (m, 2H),4.23 (d, J = 6.8 Hz, 2H), 3.79–3.74 (m, 2H), 3.76–3.68 (m, 4H), 3.67–3.60 (m,2H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02 (m, 1H), 2.86 (ddd, J =12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.39 (d, J =0.9 Hz, 3H), 2.21–2.11 (m, 1H), 2.07 (dtd, J = 12.1, 5.9, 3.5 Hz, 2H), 1.81–1.64 (m, 6H).
[0039] Example 6 A pyridopyrimidine compound, the structure of which is shown in F6, is named (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(phenyl)methyl ketone.
[0040] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of benzoyl chloride.
[0041] The characterization results of compound F6 are as follows: 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.56–7.47 (m, 1H), 7.51–7.43 (m, 4H), 7.34–7.28 (m, 2H),4.23 (d, J = 6.8 Hz, 2H), 3.79–3.74 (m, 2H), 3.76–3.68 (m, 4H), 3.67–3.60 (m,2H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02 (m, 1H), 2.86 (ddd, J =12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.20–2.10 (m,1H), 2.07 (dtd, J = 12.1, 5.9, 3.5 Hz, 2H), 1.81–1.64 (m, 6H).
[0042] Example 7 A pyridopyrimidine compound, the structure of which is shown in F7, is named (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one.
[0043] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of butenoyl chloride.
[0044] The characterization results of compound F7 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 6.88 (dq, J = 15.0, 6.1 Hz, 1H), 6.28(dq, J = 14.8, 1.5 Hz, 1H), 4.23 (d, J = 6.8 Hz, 2H), 3.84–3.77 (m, 2H), 3.79–3.70 (m, 6H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02 (m, 1H),2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.16 (tt, J = 6.9, 6.0 Hz, 1H), 2.07 (dtd, J = 12.1, 6.0, 3.5 Hz, 2H), 1.90(dd, J = 5.9, 1.5 Hz, 3H), 1.81–1.64 (m, 6H).
[0045] Example 8 A pyridopyrimidine compound, the structure of which is shown in F8, is named 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentane-1-one.
[0046] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of isohexyl chloride.
[0047] The characterization results of compound F8 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.70 (ddd, J= 6.7, 5.7, 3.8 Hz, 4H), 3.63–3.48 (m, 9H), 3.10–3.02 (m, 1H), 2.86 (ddd, J =12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.38–2.21 (m,2H), 2.20–2.12 (m, 1H), 2.07 (dtd, J = 12.1, 5.9, 3.5 Hz, 2H), 1.81–1.64 (m,8H), 1.53 (td, J = 8.8, 6.8 Hz, 2H), 0.91 (d, J = 6.8 Hz, 6H).
[0048] Example 9 A pyridopyrimidine compound, the structure of which is shown in F9, is named cyclopropyl(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl) methyl ketone.
[0049] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar equivalent of hexanoyl chloride.
[0050] The characterization results of compound F9 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.70 (ddd, J= 6.7, 5.7, 3.8 Hz, 4H), 3.63–3.48 (m, 9H), 3.10–3.02 (m, 1H), 2.86 (ddd, J =12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.37 (t, J =7.5 Hz, 2H), 2.25 (s, 2H), 2.16 (tt, J = 6.9, 6.0 Hz, 1H), 2.07 (dtd, J =12.1, 6.0, 3.5 Hz, 2H), 1.81–1.64 (m, 6H), 1.57 (p, J = 7.6 Hz, 2H), 1.40–1.28 (m, 4H), 0.92–0.85 (m, 3H).
[0051] Example 10 A pyridopyrimidine compound, the structure of which is shown in F10, is named (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenylprop-2-en-1-one.
[0052] The preparation method is the same as in Example 1, except that in step (5), acryloyl chloride is replaced with an equimolar amount of 3-phenylacryloyl chloride.
[0053] The characterization results of compound F10 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.60–7.54 (m, 2H), 7.45 (dd, J = 15.5, 0.9 Hz, 1H), 7.41–7.28 (m, 5H), 6.68 (d, J = 15.6 Hz, 1H), 4.23 (d, J = 6.8 Hz, 2H), 3.81 (ddd,J = 6.8, 3.7, 1.8 Hz, 2H), 3.79–3.70 (m, 6H), 3.54 (qdd, J = 12.5, 5.9, 3.6Hz, 4H), 3.10–3.02 (m, 1H), 2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd,J = 12.4, 8.2, 6.1 Hz, 2H), 2.16 (tt, J = 6.9, 6.0 Hz, 1H), 2.07 (dtd, J =12.1, 6.0, 3.5 Hz, 2H), 1.81–1.64 (m, 6H).
[0054] Example 11 A pyridopyrimidine compound, the structure of which is shown in F11, is named 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one.
[0055] The preparation method is the same as in Example 1, except that in step (4), 4-morpholinophenylboronic acid is replaced with an equimolar equivalent of 5-pyrimidineboronic acid.
[0056] The characterization results of compound F11 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 9.38 (d, J =1.8 Hz, 2H), 9.07 (t, J = 1.7 Hz, 1H), 8.97 (s, 1H), 6.44 (t, J = 11.5 Hz,1H), 6.09 (dd, J = 11.6, 2.3 Hz, 1H), 5.88 (dd, J = 11.5, 2.4 Hz, 1H), 4.23 (d, J = 6.8 Hz, 2H), 3.83–3.70 (m, 8H), 2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 2H), 2.21–2.10 (m, 1H), 1.81–1.67 (m,4H).
[0057] Example 12 A pyridopyrimidine compound, the structure of which is shown in F12, is named (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one.
[0058] The preparation method is the same as in Example 7, except that in step (4), 4-morpholinophenylboronic acid is replaced with an equimolar equivalent of 5-pyrimidineboronic acid.
[0059] The characterization results of compound F12 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 9.38 (d, J =1.8 Hz, 2H), 9.07 (t, J = 1.7 Hz, 1H), 8.97 (s, 1H), 6.88 (dq, J = 15.0, 6.0Hz, 1H), 6.28 (dq, J = 14.8, 1.6 Hz, 1H), 4.23 (d, J = 6.8 Hz, 2H), 3.84–3.70(m, 8H), 2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J = 12.4, 8.2, 6.1Hz, 2H), 2.21–2.10 (m, 1H), 1.90 (dd, J = 5.9, 1.5 Hz, 3H), 1.81–1.67 (m,4H).
[0060] Example 13 A pyridopyrimidine compound, the structure of which is shown in F13, is named (E)-1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenyl-2-propen-1-one.
[0061] The preparation method is the same as in Example 10, except that in step (4), 4-morpholinophenylboronic acid is replaced with an equimolar equivalent of 5-pyrimidineboronic acid.
[0062] The characterization results of compound F13 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 9.38 (d, J =1.8 Hz, 2H), 9.07 (t, J = 1.7 Hz, 1H), 8.97 (s, 1H), 7.60–7.54 (m, 2H), 7.45(dd, J = 15.5, 0.9 Hz, 1H), 7.41–7.34 (m, 2H), 7.37–7.29 (m, 1H), 6.68 (d, J= 15.6 Hz, 1H), 4.23 (d, J = 6.8 Hz, 2H), 3.81 (ddd, J = 6.8, 3.7, 1.8 Hz, 2H), 3.79–3.70 (m, 6H), 2.86 (ddd, J = 12.4, 8.3, 6.2 Hz, 2H), 2.53 (ddd, J =12.4, 8.3, 6.1 Hz, 2H), 2.16 (tt, J = 6.9, 6.0 Hz, 1H), 1.81–1.67 (m, 4H).
[0063] Example 14 A pyridopyrimidine compound, the structure of which is shown in F14, is named 1-(4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)hexane-1-one.
[0064] The preparation method is the same as in Example 9, except that in step (4), 4-morpholinophenylboronic acid is replaced with an equimolar amount of 5-pyrimidineboronic acid.
[0065] The characterization results of compound F14 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 9.38 (d, J =1.8 Hz, 2H), 9.07 (t, J = 1.7 Hz, 1H), 8.97 (s, 1H), 4.23 (d, J = 6.8 Hz,2H), 3.70 (ddd, J = 6.7, 5.7, 2.37 (t, J = 7.5 Hz, 2H), 2.25 (s, 2H), 2.21–2.10 (m, 1H), 1.81–1.67 (m,4H), 1.62–1.53 (m, 1H), 1.40–1.28 (m, 4H), 0.92–0.85 (m, 3H).
[0066] Example 15 A pyridopyrimidine compound, the structure of which is shown in F15, is named (4-(8-fluoro-2-((1-methylpiperidin-4-yl)methoxy)-7-(pyrimidin-5-yl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(p-tolyl) methyl ketone.
[0067] The preparation method is the same as in Example 5, except that in step (4), 4-morpholinophenylboronic acid is replaced with an equimolar equivalent of 5-pyrimidineboronic acid.
[0068] The characterization results of compound F15 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 9.38 (d, J =1.8 Hz, 1H), 7.49–7.43 (m, 1H), 7.16–7.10 (m, 1H), 4.23 (d, J = 6.8 Hz, 1H), 3.79–3.74 (m, 1H), 3.76–3.69 (m, 2H), 3.67–3.60 (m, 1H), 2.86 (ddd, J = 12.4,8.3, 6.2 Hz, 1H), 2.53 (ddd, J = 12.4, 8.2, 6.1 Hz, 1H), 2.39 (d, J = 1.0 Hz,1H), 2.21–2.10 (m, 0H), 1.81–1.67 (m, 2H).
[0069] Example 16 A pyridopyrimidine compound, the structure of which is shown in F16, is named 1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one.
[0070] The preparation method is the same as in Example 1, except that in step (3), 1-methyl-4-piperidinemethanol is replaced with an equimolar amount of piperol.
[0071] The characterization results of compound F16 are as follows: 1 H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 6.93 (ddt, J = 8.8, 1.8, 1.0 Hz, 1H), 6.84 (dt, J = 1.8, 1.0 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 6.44 (t, J = 11.5Hz, 1H), 6.09 (dd, J = 11.6, 2.3 Hz, 1H), 5.95–5.85 (m, 3H), 5.35 (t, J = 1.0Hz, 2H), 3.83–3.70 (m, 9H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02(m, 1H), 2.07 (dtd, J = 12.1, 5.9, 3.5 Hz, 2H), 1.68 (dtd, J = 12.3, 6.0, 3.7Hz, 2H).
[0072] Example 17 A pyridopyrimidine compound, the structure of which is shown in F17, is named (E)-1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one.
[0073] The preparation method is the same as in Example 7, except that in step (3), 1-methyl-4-piperidinemethanol is replaced with an equimolar amount of piperol.
[0074] The characterization results of compound F17 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 6.93 (ddt, J = 8.8, 1.9, 1.0 Hz, 1H),6.93–6.84 (m, 1H), 6.84 (dt, J = 1.8, 1.0 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 6.28 (dq, J = 14.8, 1.5 Hz, 1H), 5.93 (s, 2H), 5.35 (t, J = 1.0 Hz, 2H),3.84–3.70 (m, 8H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02 (m, 1H), 2.07 (dtd, J = 12.1, 5.9, 3.5 Hz, 2H), 1.90 (dd, J = 6.0, 1.6 Hz, 3H), 1.68(dtd, J = 12.3, 6.0, 3.7 Hz, 2H).
[0075] Example 18 A pyridopyrimidine compound, the structure of which is shown in F18, is named 1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentanone.
[0076] The preparation method is the same as in Example 8, except that in step (3), 1-methyl-4-piperidinemethanol is replaced with an equimolar amount of piperol.
[0077] The characterization results of compound F18 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 6.93 (ddt, J = 8.8, 1.9, 1.0 Hz, 1H), 6.84 (dt, J = 1.9, 1.0 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 5.93 (s, 2H), 5.35 (t, J = 1.0 Hz, 2H), 3.70 (ddd, J = 6.7, 5.7, 3.8 Hz, 4H), 3.63–3.48 (m, 9H),3.10–3.02 (m, 1H), 2.38–2.21 (m, 2H), 2.07 (dtd, J = 12.1, 6.0, 3.5 Hz, 2H), 1.76–1.64 (m, 3H), 1.53 (td, J = 8.8, 6.8 Hz, 2H), 0.91 (d, J = 6.8 Hz, 6H).
[0078] Example 19 A pyridopyrimidine compound, the structure of which is shown in F19, is named (4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)(cyclopropyl)methyl ketone.
[0079] The preparation method is the same as in Example 2, except that in step (3), 1-methyl-4-piperidinemethanol is replaced with an equimolar amount of piperol.
[0080] The characterization results of compound F19 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.34–7.28 (m, 2H), 6.93 (ddt, J = 8.8, 1.9, 1.0 Hz, 1H), 6.84 (dt, J = 1.9, 1.0 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 5.93 (s, 2H), 5.35 (t, J = 1.0 Hz, 2H), 3.78–3.65 (m, 6H), 3.64–3.48 (m, 6H), 3.10–3.02 (m, 1H),2.07 (dtd, J = 12.1, 6.0, 3.5 Hz, 2H), 1.87 (q, J = 6.4 Hz, 1H), 1.68 (dtd, J= 12.3, 6.0, 3.7 Hz, 2H), 0.91–0.77 (m, 5H).
[0081] Example 20 A pyridopyrimidine compound, the structure of which is shown in F20, is named (E)-1-(4-(2-(benzyl(E)-1-(4-(2-(benzo[d][1,3]dioxolane-5-ylmethoxy)-8-fluoro-7-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin[4,3-d]pyrimidin-4-yl)piperazin-1-yl)-3-phenyl-2-propen-1-one.
[0082] The preparation method is the same as in Example 10, except that in step (3), 1-methyl-4-piperidinemethanol is replaced with an equimolar amount of piperol.
[0083] The characterization results of compound F20 are as follows: 1H NMR (400 MHz, Chloroform-d) δ 8.80 (s, 1H),7.87–7.81 (m, 2H), 7.60–7.54 (m, 2H), 7.45 (dd, J = 15.5, 0.9 Hz, 1H), 7.41–7.28 (m, 5H), 6.93 (ddt, J = 8.8, 1.8, 1.0 Hz, 1H), 6.84 (dt, J = 1.9, 1.0Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 6.68 (d, J = 15.6 Hz, 1H), 5.93 (s, 2H),5.35 (t, J = 1.0 Hz, 2H), 3.81 (ddd, J = 6.8, 3.7, 1.8 Hz, 2H), 3.79–3.70 (m,6H), 3.54 (qdd, J = 12.5, 5.9, 3.6 Hz, 4H), 3.10–3.02 (m, 1H), 2.07 (dtd, J =12.1, 5.9, 3.5 Hz, 2H), 1.68 (dtd, J = 12.3, 6.0, 3.7 Hz, 2H).
[0084] Performance testing 1. Validation of in vitro anti-tumor cell activity (1) Cell (H358 non-small cell lung cancer cells) plating: After the cells in the culture flask reached 80% confluence, the cell pellet was collected by digestion and centrifugation, and the supernatant was discarded. An appropriate amount of cells was added to 1 mL of culture medium for resuspending and mixing. Cells were counted under a microscope using a cell counting chamber, and the cell density was adjusted to 20,000–25,000 cells / mL. In a 96-well plate, 180 µL of PBS was added to each well in rows A and H and column 1, and 180 µL of cell suspension was added to each well in row B and G. The plates were then incubated at 37 °C in a 5% CO2 incubator for 24 h. After the cells grew to a suitable density, subsequent drug addition experiments could be carried out.
[0085] (2) Drug treatment: Five drug concentration gradients were set up for the experiment, namely 100.0, 33.3, 11.1, 3.7 and 1.2 μM. 1 mg of drug was placed in a 1.5 mL centrifuge tube, 20 µL of cell culture grade DMSO was added and thoroughly dissolved by pipetting, and then 980 µL of serum-free culture medium was added and mixed well to prepare the drug stock solution. The working solution was obtained by serially diluting the drug four times using a 3-fold serial dilution method. When adding the drug, the operation was carried out sequentially from low concentration to high concentration, with 2 replicates for each concentration. 20 µL of drug solution was added to each well, and a control group without drug was also set up. Each 96-well plate can detect 4 drugs at the same time. After drug addition, the plate was placed in a 37 ℃, 5% CO2 incubator for 72 h.
[0086] (3) Preparation of MTT reagent: Under light-protected conditions, MTT powder was diluted to 50 mL with PBS, filtered through a 0.22 μm filter membrane for sterilization, wrapped in aluminum foil to protect from light, and stored in a refrigerator at 4 °C for later use.
[0087] (4) MTT assay: After 72 h of drug treatment, the culture medium in the wells was discarded, and 20 µL of MTT solution was added to each well. The wells were then returned to the incubator for another 4 h of incubation. After incubation, the supernatant was removed, and DMSO was added to each well. The formazan product was dissolved by shaking thoroughly. Finally, the absorbance (OD value) of each well was detected using a microplate reader.
[0088] (5) Inhibition rate calculation formula: IR% = (OD control - OD sample) / (OD control - OD blank) × 100% The results of the inhibitory activity of the pyridopyrimidine compounds prepared in Examples 1-20 on H358 non-small cell lung cancer cells are shown in Table 1, where NA represents IC50. 50 If the value is greater than 1000, ND indicates that no detection was performed.
[0089] Table 1 Antiproliferative activity (IC50) 50 (Measurement) As shown in Table 1, the compounds prepared in the embodiments of this application have good in vitro anti-cell proliferation activity. Among them, F1 and F7 showed excellent inhibition rates against H358 cells. It can be seen that the compounds prepared in the embodiments of this application are expected to become a potential inhibitor of KRAS kinase.
[0090] 2. Evaluation of hemolytic toxicity Hemolytic toxicity tests were performed on compound F1. 1% Triton was used as a positive control, and physiological saline was used as a negative control.
[0091] First, 4% sheep red blood cells were added to a centrifuge tube and centrifuged at 3000 rpm for 5 min at low temperature. The preservation solution was then discarded, and physiological saline was added to a final volume of 1.5 mL, followed by another 5 min centrifugation. Next, 1% Triton was prepared as a positive solution, physiological saline as a negative solution, and different concentrations of compound dilution buffers were prepared. The experimental samples were then incubated at 37 °C for 1 h; the experimental phenomena were recorded by photographing under fluorescent light. Finally, the supernatant was collected and the absorbance was measured at 540 nm using a UV spectrophotometer, and the hemolysis rate of the compound was calculated according to the formula.
[0092] Hemolysis rate (%) = (A experimental group – A negative control group) / (A positive control group – A negative control group).
[0093] Figure 1 The results of the hemolytic safety evaluation of compound F1 are shown (where 16 represents a concentration of 16 μg / mL of compound F1, and so on; the inset shows photographs of the hemolysis test results, corresponding to the horizontal axis from left to right). The results show that the hemolysis rate of compound F1 at 256 μg / mL is only 4.97%. With increasing compound concentration, the hemolysis rate gradually increases, but the overall hemolytic toxicity remains at a low level. Notably, the hemolysis rate at all tested concentrations is below 5%. This indicates that compound F1 has a weak destructive effect on the erythrocyte membrane within the set concentration range, exhibiting good blood compatibility. The low hemolytic toxicity suggests that compound F1 may have high safety in in vivo applications, and its hemolytic toxicity to cancer is safe.
[0094] 3. KM mouse toxicity test Healthy KM mice were selected for this experiment and randomly divided into three groups according to the principle of balanced body weight. Individual animals were identified by ear tags. The experimental groups were as follows: ARS-1620 positive control group (dose 120 mg / kg), saline blank control group (administered an equal volume of saline), and compound F1 administration group (dose 120 mg / kg). Mice in each group were administered the drug via gavage once daily at a dose of 60 mg / kg, and body weight changes were continuously observed and recorded over one week.
[0095] After the drug administration phase, blood was collected from the eyeballs of mice, and the collected whole blood was transferred to 1.5 mL EP tubes. 150 µL of whole blood sample was transferred to a dedicated biochemical assay kit, and ten relevant preoperative biochemical indicators were measured using a fully automated multifunctional biochemical analyzer. Data were recorded and statistically analyzed simultaneously. After blood collection, the mice were dissected, and vital organs such as the heart, liver, spleen, lungs, and kidneys were carefully separated and completely removed. These organs were fixed in 4% paraformaldehyde fixative and sent to Wuhan Sewell Biotechnology Co., Ltd. for hematoxylin and eosin analysis. Eosin (HE) staining and pathological analysis.
[0096] The specific steps for HE staining are as follows: (1) First, the mouse organs and tissues were rinsed with physiological saline, and after the surface moisture was dried, they were fixed in 4% formaldehyde solution for 24 h. After the tissues were fixed, they were placed in 50%, 70%, 80% and 90% ethanol solutions by volume, and each concentration was used for dehydration treatment for 1 h.
[0097] (2) The dehydrated tissue was cleared with xylene twice, for 15 min each time; then the tissue was immersed in molten paraffin for 2 h. After preparing the paraffin sections, they were placed in xylene I, xylene II, anhydrous ethanol I, anhydrous ethanol II and 75% ethanol in sequence for 20 min, 20 min, 5 min, 5 min and 5 min respectively. Finally, the sections were slowly rinsed with tap water.
[0098] (3) Immerse the sections in hematoxylin staining solution for 3-5 min, remove and rinse with tap water, differentiate with differentiation solution, rinse again with running water, then re-blue the tissue with blue solution and rinse thoroughly with running water. Next, immerse the sections in 85% and 95% ethanol for 5 min each, then immerse them in eosin staining solution for 5 min. After staining, place the sections in anhydrous ethanol I, anhydrous ethanol II, anhydrous ethanol III, xylene I, and xylene II in sequence for 5 min each, and finally mount with neutral resin.
[0099] (4) Use an optical microscope to observe, photograph and save the tissue sections of each group, and analyze and evaluate the experimental results based on the pathological images.
[0100] The results of the in vivo toxicity test of each group in KM mice are shown below. Figure 2 The study included biochemical indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (CREA), total protein (TP), urea (UREA), blood glucose (GLU), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and creatine kinase (CK). Among these indicators, compound F1 had a slight effect on the physiological indicators of KM mice, but none exceeded the normal physiological range, and it had no significant effect on blood glucose, lipid metabolism, and electrolyte levels. Overall, compound F1 did not cause significant adverse effects on the main biochemical indicators of mice within the normal dose range, further indicating its good safety profile in preclinical studies. To assess the organ toxicity of compound F1 in KM mice, histological examination of major organs (liver, kidney, spleen, heart, and lungs) was performed using hematoxylin-eosin (HE) staining. The results are as follows: Figure 3As shown, histological examination of various organs using hematoxylin-eosin staining revealed no significant structural damage in the heart, liver, spleen, lungs, and kidneys under HE staining. Myocardial fibers were regularly arranged, with normal nuclei and cytoplasm morphology, and no obvious inflammatory infiltration or structural damage was observed. The liver lobule structure was clear, hepatocyte cords were orderly arranged, and the central vein and portal areas were normal in morphology. The spleen showed no inflammatory infiltration or abnormal proliferation of splenic bodies. The alveolar structure was intact, with no significant thickening of the alveolar septa, and no signs of alveolar collapse, inflammatory cell infiltration, or fibrosis. The kidney structure was clear, the basement membrane was intact, and the renal interstitium showed no obvious abnormalities, degeneration, or necrosis; there was no inflammatory infiltration or edema in the renal interstitium. These results indicate that compound F1 did not cause serious organ damage at high doses (120 mg / kg), demonstrating good safety and providing strong support for further preclinical studies.
[0101] 4. Time Dependency Test In vitro antitumor proliferation assay of H358 tumor cell line. Each cell line was placed in a 96-well plate and cultured for 24 hours. Then, culture medium containing the compound was added to each well at five different concentrations, with each concentration repeated three times. The final drug concentrations were 100.0, 33.3, 11.1, 3.7, and 1.2 μM. After 72 h, MTT solution (5 mg / mL) was added to each well and incubated for 4 h. The MTT solution was then removed, and DMSO (150 mL) was added to each well. Finally, the optical density (OD) of each well was measured at 492 nm using an enzyme-labeled enzyme. The antiproliferative inhibition rate of the compound against tumor cells was determined by the optical density value. The inhibition rate (%) was calculated using the following formula: (OD control - OD treatment) / (OD control - OD blank) - 100%. The half-maximal inhibitory concentration (IC50) of the compound against tumor cells was calculated using SPSS software. 50 H358 cells were treated using the same method. Absorbance values were measured at 24 h, 48 h, and 72 h. The inhibition rate of H358 cells at different time points was calculated and plotted as a line graph. The results are shown below. Figure 4 As shown, the experimental results indicate that, at the same concentration, the inhibition rate steadily increased with prolonged treatment time. At a concentration of 100 μM, the inhibition rate of compound F1 on H358 cells approached 95% after 72 hours. This demonstrates that compound F1 inhibits the growth of H358 cells in a time- and concentration-dependent manner.
[0102] 5. Scratch test to assess cell migration ability (1) Cell (non-small cell lung cancer cells H358) preparation: Cells in the logarithmic growth phase were collected by trypsin digestion and cultured in complete culture medium at 1×10⁻⁶. 6 2 mL of the sample was seeded per well in a 6-well cell culture plate. The cells were incubated overnight at 37°C, depending on cell adhesion.
[0103] (2) After the cells adhere to the plate, observe that the cell density reaches more than 90%. Use a pipette tip, perpendicular to the cell plane, to make a scratch on the cell layer along the line drawn on the back of the plate the day before. Discard the supernatant, wash the cells three times with sterile PBS to remove the non-adherent cells, add the appropriate concentration of basal medium, and culture for 24 h.
[0104] The cells were incubated at 37 °C in a 5% CO2 incubator. Cells were then removed at 0 h and 24 h, and the width of the scratches was observed under a microscope and photographed.
[0105] The results are as follows Figure 5 As shown, after 24 h, control group cells clearly migrated towards the center, indicating that H358 cells can migrate normally under natural conditions. Compared to 0 h, at a drug concentration of 3 μM, compound F1 showed a significant inhibitory effect on tumor cell migration after 24 h. When the drug concentration increased to 6 μM, the ability of compound F1 to inhibit tumor cell migration was further enhanced, and at 9 μM, the effect was even stronger, approaching the inhibitory effect of the positive control ARS-1620 at 3 μM. This indicates that compound F1 inhibits H358 cell migration in a dose-dependent manner.
[0106] 6. Methods for assessing cell cloning capacity Before the experiment, H358 cells in the logarithmic growth phase were harvested, the culture medium was discarded, and the cells were digested with trypsin. The cell pellet was collected by centrifugation, resuspended in complete culture medium, and a single-cell suspension was prepared. Cells were counted using a hemocytometer, and the cell density was adjusted. Based on the cell proliferation rate, 500-2000 cells / well were seeded into 6-well culture plates. Complete culture medium was added to each well to make up the volume, and the plates were gently agitated to ensure uniform distribution of single cells and avoid cell aggregation that could affect colony formation. The seeded cells were pre-cultured at 37 ℃ in a 5% CO2 incubator for 24 h. After complete cell adhesion, a gradient concentration of compound F1 was added for further culture, with the culture medium changed periodically to observe cell growth. During observation, the culture medium was discarded, and the cells were slowly rinsed twice with PBS buffer to remove residual culture medium and dead cells. The cells were fixed with 4% paraformaldehyde at room temperature for 30 min, the fixative was discarded, and the cells were rinsed again with PBS. Crystal violet staining solution was added for 15 min at room temperature. After staining, excess stain was slowly rinsed with running water, the cells were inverted and air-dried, and photographs were taken to record the cell colony formation.
[0107] Depend on Figure 6 It can be found that compound F1 inhibits the proliferation and colony formation of H358 cells to a certain extent, and can effectively inhibit the cloning of H358 cells in a concentration-dependent manner.
[0108] 7. AO acridine orange staining experiment Acridine orange (AO) is a dye that interacts with DNA and RNA through intercalation or electrostatic attraction. It can also be used to detect apoptosis in cancer cells. Therefore, AO dye can be used to observe the effect of treatment with selected compounds on cancer cell apoptosis. Cell suspensions in the logarithmic growth phase were seeded into 24-well plates and cultured for 24 h. Different concentrations of the compound solution were then added. The 24-well plates were cultured for another 8 h before AO staining solution was added. After incubation in the dark for 15 minutes, cell morphology was observed using a fluorescence inverted microscope, and photographs were taken and stored.
[0109] Depend on Figure 7 It was observed that after 12 hours of treatment with 3 μM compound F1, H358 cells developed fragmented nuclei and densely stained green granules of varying sizes, indicating that compound F1 promoted apoptosis in H358 cells. As the drug concentration increased, the number of apoptotic bodies in the cells gradually increased, and at 9 μM, the number of apoptotic bodies was essentially the same as that of the positive control drug ARS-1620, indicating that compound F1 can induce apoptosis in H358 cells in a concentration-dependent manner.
[0110] 8. Mitochondrial membrane potential detection: JC-1 staining method JC-1 is an ideal fluorescent probe for detecting changes in mitochondrial membrane potential (MMP). This method can assess whether cells have undergone apoptosis by detecting the membrane potential of normal and apoptotic cells. H358 cells in logarithmic growth phase were seeded in 24-well plates. After culturing for 24 h, different concentrations of compound solutions were added, and after treatment with the selected compound, the cells were cultured for another 12 h. Cells were stained with JC-1 and observed under a fluorescence microscope. Then, JC-1 staining solution was added and the cells were incubated in an incubator for 30 min. Finally, the cell state was observed and photographed using a fluorescence inverted microscope.
[0111] from Figure 8 As can be seen, the control group cells exhibited orange fluorescence after staining, indicating that the intracellular MMP levels were normal. Compound F1, however, showed green fluorescence after staining, indicating that it led to a decrease in intracellular MMP levels and cell shrinkage. When the concentration of compound F1 increased to 6 and 9 μM, the green fluorescence gradually increased, indicating that compound F1 could induce apoptosis in H358 cells with increasing concentration.
[0112] 9. Methods for detecting reactive oxygen species (ROS) in cells Using cells in the logarithmic growth phase, at a density of 2.0 × 10⁶ cells per well. 5Cells were seeded at a density of [number] cells per well in 6-well plates and incubated for 24 h. Culture medium containing the target compound was added, and after the specified incubation time, the old culture medium was discarded. The cells were washed twice with PBS, and then staining solution was added. Subsequently, two more PBS washes were performed, and 1 mL of culture medium containing DCFH-DA was added to each well. Excess formaldehyde was removed, and two more PBS washes were performed. Finally, 1 mL / well of crystal violet was added for staining, and the plates were incubated for 15 minutes. After the final two PBS washes, the cells were observed and photographed using a fluorescence microscope.
[0113] The results are as follows Figure 9 As shown in the figure, almost no specific green fluorescence signal was observed in the blank control group, indicating that the target protein expression level was extremely low or unactivated under basal conditions. When treated with a low concentration of compound F1 (3 μM), the cells exhibited slight green fluorescence, indicating a small amount of ROS production. Treatment with high concentrations of compound F1 (6 μM and 9 μM) resulted in a significant increase in green fluorescence intensity, with dense and widely distributed fluorescent spots. The fluorescence intensity was comparable to that of the positive control group ARS-1620, indicating that high concentrations of compound F1 can significantly induce the expression or activation of the target protein, with an effect similar to that of the positive control drug. Compound F1 can induce the expression or activation of the target protein in H358 cells in a concentration-dependent manner, and the regulatory effect at a concentration of 9 μM is comparable to that of the positive control ARS-1620, suggesting that compound F1 can exert its biological effect by targeting this signaling pathway, providing direct mechanistic evidence for its activity against non-small cell lung cancer.
[0114] Application Example 1: Tablets 10 g of compound F1 prepared in Example 1 was weighed and mixed with 20 g of excipients according to the general pharmaceutical tableting method. The mixture was then compressed into 100 tablets, each weighing 300 mg.
[0115] Application Example 2: Capsules 5 g of compound F10 prepared in Example 10 was weighed and mixed with 10 g of excipients according to the requirements of pharmaceutical capsules. The mixture was then filled into empty capsules, each weighing 300 mg.
[0116] Application Example 3: Ointment 10 g of compound F12 prepared in Example 12 was weighed, ground into a fine powder, and then mixed with 500 g of an oily matrix such as petrolatum.
[0117] Application Example 4: Aerosol 10 g of compound F15 prepared in Example 15 was weighed, dissolved in an appropriate amount of propylene glycol, and then distilled water and other excipients were added to prepare a 500 mL clear solution.
[0118] Application Example 5: Suppositories 10 g of compound F20 prepared in Example 20 was weighed, ground into a fine powder, and then an appropriate amount of glycerin was added. After grinding evenly, melted glycerin gelatin was added and ground evenly. The powder was then poured into a mold coated with lubricant to prepare 50 suppositories.
[0119] Application Example 6: Droplets 5 g of compound F11 prepared in Example 11 was weighed and mixed with 25 g of matrix such as gelatin. After heating and melting, the mixture was dropped into low-temperature liquid paraffin to prepare 1000 pills.
[0120] Application Example 7: Topical Liniments 10 g of compound F13 prepared in Example 13 was weighed and mixed with 2.5 g of excipients such as emulsifier according to conventional pharmaceutical methods and ground. Then, distilled water was added to 200 mL to obtain the final product.
[0121] Application Example 8: Injectables 6 g of compound F16 prepared in Example 16 was weighed and adsorbed onto activated carbon according to conventional pharmaceutical methods. After filtration through a 0.65 μm microporous membrane, the solution was filled into a nitrogen tank to prepare an aqueous injection, with each vial containing 2 mL. A total of 100 vials were filled.
[0122] Application Example 9: Film Formulation Polyvinyl alcohol, pharmaceutical glycerin, water, etc. are stirred and expanded, then heated and dissolved. The mixture is filtered through an 80-mesh sieve. Compound F15 prepared in Example 15 is then added to the filtrate and stirred and dissolved. 100 films are made by coating the film.
[0123] The above description is merely a preferred embodiment of this application. This application is not limited to the above-described embodiments. Any embodiment that achieves the technical effect of this application using the same means should fall within the protection scope of this application. Within the protection scope of this application, the technical solutions and / or implementation methods can have various modifications and variations.
Claims
1. A pyridopyrimidine compound, characterized in that, Its structure is shown in Equation I, Equation II, or Equation III: Formula I; Formula II; Formula III; Where R is selected from , , , , , , , , and One of them.
2. The pyridopyrimidine compound according to claim 1, characterized in that, The pyridopyrimidine compounds have structural formulas of any one of formulas F1-F20: 。 3. The pyridopyrimidine compound according to claim 2, characterized in that, The structural formulas of the pyridopyrimidine compounds are shown in Formula F1 or Formula F7.
4. A method for preparing a pyridopyrimidine compound according to any one of claims 1 to 3, characterized in that, This includes synthesis route one, synthesis route two, or synthesis route three, wherein synthesis route one is: ; The second synthetic route is as follows: ; The third synthetic route is as follows: 。 5. A pharmaceutical composition, characterized in that, This includes pyridopyrimidine compounds as described in any one of claims 1 to 3, or pharmaceutically acceptable salts thereof.
6. The pharmaceutical composition according to claim 5, characterized in that, The pharmaceutical composition further includes a pharmaceutically acceptable carrier or excipient; and / or, the dosage form of the pharmaceutical composition is an injection, tablet, capsule, aerosol, suppository, film, pellet, liniment, or ointment.
7. The use of a pyridopyrimidine compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 5 or 6, in the preparation of a KRAS-targeting inhibitor.
8. The use of a pyridopyrimidine compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 5 or 6, in the preparation of a medicament for treating and / or preventing cancer.
9. The application according to claim 8, characterized in that, The cancer in question is breast cancer, lung cancer, melanoma, pancreatic cancer, or prostate cancer.
10. The use of a pyridopyrimidine compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 5 or 6, in the preparation of a medicament for the treatment and / or prevention of proliferative diseases.
